Merck & Co is a global healthcare company that specializes in the development, manufacturing, and marketing of pharmaceutical products and vaccines. The company is dedicated to improving health outcomes through innovative research and is known for its focus on areas such as oncology, infectious diseases, and immunology. In addition to its pharmaceutical offerings, Merck actively engages in the discovery of new biologics and therapies, working to address some of the most pressing health challenges worldwide. Through its commitment to scientific excellence and patient care, Merck plays a critical role in advancing public health and enhancing quality of life globally. Read More
As of December 12, 2025, the financial markets are witnessing a significant "Great Rotation," a pronounced shift of capital from high-growth technology and Artificial Intelligence (AI) stocks to more traditional value sectors and defensive equities. This ongoing recalibration reflects evolving macroeconomic conditions, a reassessment of risk appetite, and a growing
The semiconductor industry, the foundational bedrock of our digital world and the engine powering the explosive growth of artificial intelligence, is undergoing a profound transformation. Driven by escalating environmental concerns, stringent regulatory demands, and a heightened sense of corporate responsibility, chip manufacturers are increasingly prioritizing energy efficiency and sustainable practices in every facet of chip [...]
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended the approval of an expanded indication for WINREVAIR™ (sotatercept), in combination with other pulmonary arterial hypertension (PAH) therapies, for the treatment of PAH in adult patients with WHO Functional Class (FC) II, III, and IV based on the Phase 3 ZENITH study. The currently approved indication in the European Union (EU) is for adults with PAH with WHO FC II to III, to improve exercise capacity. The CHMP recommendation will now be reviewed by the European Commission (EC) for amending the marketing authorization in the EU, Iceland, Liechtenstein and Norway, and a final decision is expected in the first quarter of 2026.
Megacap stocks are behemoths that set the tone for their industries, and their massive scale typically leads to wide moats.
However, the downside is that most have already exploited their existing market opportunities and must invest heavily to expand further, a risky proposition.
New York, NY – December 9, 2025 – The S&P 500 Healthcare sector found itself in a precarious position today, emerging as the biggest underperformer among its peers. While the broader S&P 500 index largely treaded water, the healthcare segment registered a notable decline of 0.5%, extending a three-day
Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Tuesday as we examine the latest happenings in today's session.
Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the U.S. Food and Drug Administration (FDA) has granted a conditional approval for EXZOLT™ CATTLE-CA1 (fluralaner topical solution). This innovative product is in the newest class of parasiticides known as isoxazolines. The pour-on solution is effective for the prevention and treatment of infestations caused by New World screwworm (Cochliomyia hominivorax) larvae (myiasis). It is also conditionally approved for the treatment and control of cattle fever tick (Rhipicephalus microplus).
The global prescription drugs market is on the cusp of a significant expansion, with recent market reviews and forecasts projecting a robust growth trajectory through 2035. This anticipated surge, driven by an aging global population, the rising prevalence of chronic diseases, and relentless innovation in pharmaceutical research and development, signals
Wall Street has recently concluded a tumultuous yet ultimately resilient period, with the Dow Jones Industrial Average, S&P 500, and Nasdaq Composite all managing to edge higher in late November and early December 2025. This cautious comeback signals a complex market sentiment, where investors are meticulously weighing the promise
BioMedWire Editorial Coverage : Chronic conditions and rare diseases in the aging population present an urgent and expanding challenge within the U.S. healthcare system, especially as more than 30 million Americans are affected by rare diseases, according to the National Institutes of Health. The vast majority of these conditions lack any FDA-approved treatment, leaving older adults especially vulnerable as age-related symptoms often obscure or delay diagnosis. This rising burden has increased demand for new therapies that can address real unmet need. Soligenix Inc. (NASDAQ: SNGX) ( Profile ), a late-stage biopharmaceutical company, is developing multiple treatments for rare diseases, including HyBryte[TM] (synthetic hypericin) for cutaneous T-cell lymphoma, and is now conducting the final confirmatory clinical study required before filing for worldwide marketing approval. As the Trump administration advances new health policy initiatives affecting chronic and rare diseases, Soligenix’s work sits at a critical intersection of medical innovation and national health priorities. The company is working alongside several leading companies committed to making an impact in the pharmaceutical and life sciences space, including Pfizer Inc. (NYSE: PFE), Merck & Co Inc. (NYSE: MRK), Bristol-Myers Squibb Co. (NYSE: BMY) and…
AUSTIN, Texas, Dec. 02, 2025 (GLOBE NEWSWIRE) -- BioMedWire: Chronic conditions and rare diseases in the aging population present an urgent and expanding challenge within the U.S. healthcare system, especially as more than 30 million Americans are affected by rare diseases, according to the National Institutes of Health. The vast majority of these conditions lack any FDA-approved treatment, leaving older adults especially vulnerable as age-related symptoms often obscure or delay diagnosis. This rising burden has increased demand for new therapies that can address real unmet need. Soligenix Inc. (NASDAQ: SNGX) (Profile), a late-stage biopharmaceutical company, is developing multiple treatments for rare diseases, including HyBryte[TM] (synthetic hypericin) for cutaneous T-cell lymphoma, and is now conducting the final confirmatory clinical study required before filing for worldwide marketing approval. As the Trump administration advances new health policy initiatives affecting chronic and rare diseases, Soligenix’s work sits at a critical intersection of medical innovation and national health priorities. The company is working alongside several leading companies committed to making an impact in the pharmaceutical and life sciences space, including Pfizer Inc. (NYSE: PFE), Merck & Co Inc. (NYSE: MRK), Bristol-Myers Squibb Co. (NYSE: BMY) and Insmed Inc. (NASDAQ: INSM).
